中国肺癌杂志Issue(4)：357-362,6.DOI:10.3779/j.issn.1009-3419.2014.04.12
EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展
Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
李夏南 1朱广迎2
作者信息
- 1. 100044北京，北京大学人民医院
- 2. 100142北京，北京市肿瘤防治研究所，恶性肿瘤发病机制及转化研究教育部重点实验室，北京大学肿瘤医院
- 折叠
摘要
Abstract
Lung cancer is one of the most common malignant tumor in the world, severely threatening human life. Recently, targeted therapy such as the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) made huge progress in treatment of lung cancer. EGFR-TKIs, with its high selectivity and low toxicity, is the ifrst choice for EGFR-mutated patients in stage IV non-small cell lung cancer (NSCLC). However, secondary drug resistance becomes a clinical problem to be urgently resolved. In recent years, a series of preclinical studies showed that EGFR-TKI can enhance the antitumor activ-ity of ionizing radiation. hTerefore, EGFR-TKI combined with radiation is extremely promising therapy pattern for advanced NSCLC. hTis review will discuss the research status in EGFR-TKI and radiotherapy for advanced NSCLC.关键词
EGFR-TKI/放疗/肺肿瘤Key words
EGFR-TKI/Radiotherapy/Lung neoplasms引用本文复制引用
李夏南,朱广迎..EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国肺癌杂志,2014,(4):357-362,6.
